A new Ebola vaccine that was developed by the Oxford University team that made the AstraZeneca Covid jab is being trialed in humans for the first time.
The jab uses the same technology as the breakthrough Coronavirus shot.
It has been designed to tackle the Zaire and Sudan strains of Ebola, the two most common and deadly types.
The trial will see 26 people between the ages of 18 and 55 given the jab and monitored over a six-month period in Oxford. Another trial is due to start in Tanzania by the end of the year.
Patients will begin to be vaccinated from this week and results are expected in the second half of 2022.